2010
DOI: 10.1097/ta.0b013e3181d32271
|View full text |Cite
|
Sign up to set email alerts
|

Standard Prophylactic Enoxaparin Dosing Leads to Inadequate Anti-Xa Levels and Increased Deep Venous Thrombosis Rates in Critically Ill Trauma and Surgical Patients

Abstract: Standard dosing of enoxaparin leads to low anti-Xa levels in half of surgical ICU patients. Low levels are associated with a significant increase in the risk of DVT. These data support future studies using adjusted-dose enoxaparin.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
157
0
1

Year Published

2011
2011
2022
2022

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 151 publications
(164 citation statements)
references
References 28 publications
6
157
0
1
Order By: Relevance
“…However, evidence that implementation of anti-Xa monitoring might reduce the risk of VTE in critically ill patients is still scarce [23]. Variability and lack of standardization are the most relevant drawbacks of anti-Xa assays [24], and evidence of a strong relationship between anti-Xa and the occurrence of thromboembolic events is still lacking [25].…”
Section: 00mentioning
confidence: 99%
“…However, evidence that implementation of anti-Xa monitoring might reduce the risk of VTE in critically ill patients is still scarce [23]. Variability and lack of standardization are the most relevant drawbacks of anti-Xa assays [24], and evidence of a strong relationship between anti-Xa and the occurrence of thromboembolic events is still lacking [25].…”
Section: 00mentioning
confidence: 99%
“…24 Indeed while much of the existing literature has focused on altered antibiotic drug handling with this phenomenon, 25,26 ARC has the potential to influence the pharmacokinetics of any renally cleared agent. Examples in the neurocritical care environment include low molecular weight heparins, 27,28 and anti-seizure medications, 29 both of which manifest largely silent pharmacodynamic endpoints. In this fashion, inadequate dosing in the setting of ARC primarily manifests as adverse clinical consequences from treatment failure (e.g.…”
Section: Page 14 Of 28mentioning
confidence: 99%
“…Recent studies show that VTE rates may be directly correlated with anti-factor Xa activity levels, so some VTE prophylaxis protocols incorporate activity level monitoring to ensure adequacy [22]. Activity level monitoring is generally not available prior to role 3 care and consensus does not exist for the monitoring requirement.…”
Section: Prevention Of Deep Venous Thrombosismentioning
confidence: 99%